000			01442 a2200397 4500
005			20250514201741.0
264		0	_c20041116
008			200411s 0 0 eng d
022			_a0145-2126
024	7		_a10.1016/j.leukres.2004.03.003 _2doi
040			_aNLM _beng _cNLM
100	1		_aMalek, Karim
245	0	0	_aEffects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies. _h[electronic resource]
260			_bLeukemia research _cNov 2004
300			_a1125-36 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aEnzyme Inhibitors _xtherapeutic use
650	0	4	_aFemale
650	0	4	_aGenes, abl
650	0	4	_aHumans
650	0	4	_aIMP Dehydrogenase _xantagonists & inhibitors
650	0	4	_aLeukemia, Myeloid, Acute _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aRibavirin _xanalogs & derivatives
650	0	4	_aTreatment Outcome
700	1		_aBoosalis, Michael S
700	1		_aWaraska, Kristin
700	1		_aMitchell, Beverly S
700	1		_aWright, Daniel G
773	0		_tLeukemia research _gvol. 28 _gno. 11 _gp. 1125-36
856	4	0	_uhttps://doi.org/10.1016/j.leukres.2004.03.003 _zAvailable from publisher's website
999			_c15073578 _d15073578